Cardio Diagnostics Holdings, Inc. (CDIO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardio Diagnostics Holdings, Inc. (CDIO) with AI Score 42/100 (Weak). Cardio Diagnostics Holdings, Inc. focuses on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Cardio Diagnostics Holdings, Inc. (CDIO) Healthcare & Pipeline Overview
Cardio Diagnostics Holdings, Inc. is a biotechnology company specializing in epigenetics-based clinical tests for cardiovascular disease, primarily offering the Epi+Gen CHD risk assessment test. The company operates within the competitive healthcare sector, focusing on innovative diagnostic solutions for personalized medicine.
Investment Thesis
Cardio Diagnostics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on epigenetics-based cardiovascular disease diagnostics offers potential for significant growth, driven by the increasing demand for personalized medicine and early disease detection. However, the company's negative profit margin of -43832.5% and gross margin of -2180.2% indicate significant financial challenges. The company's success hinges on the successful commercialization and adoption of its Epi+Gen CHD test. Upcoming catalysts include potential partnerships with healthcare providers and expansion of its product line. Potential risks include competition from established diagnostic companies, regulatory hurdles, and the need for additional funding to support operations and growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -0.79 reflects the company's current lack of profitability.
- Profit margin of -43832.5% highlights the company's significant expenses relative to its revenue.
- Gross margin of -2180.2% indicates that the cost of goods sold exceeds revenue, suggesting potential issues with pricing or production costs.
- Beta of 2.23 suggests the stock is more volatile than the market, indicating higher risk and potential reward.
Competitors & Peers
Strengths
- Innovative epigenetics-based technology
- Focus on personalized medicine
- Potential for early disease detection
- Proprietary Epi+Gen CHD test
Weaknesses
- Negative profit margin
- Negative gross margin
- Limited financial resources
- Small number of employees
Catalysts
- Upcoming: Potential partnerships with healthcare providers to integrate Epi+Gen CHD into diagnostic protocols.
- Upcoming: Expansion of the product line to include additional epigenetics-based diagnostic tests for other cardiovascular conditions.
- Ongoing: Continued commercialization and adoption of Epi+Gen CHD test.
- Ongoing: Research and development efforts to further enhance the company's epigenetics-based technology.
Risks
- Potential: Competition from established diagnostic companies with greater financial and marketing resources.
- Potential: Regulatory hurdles and the need for FDA approval for new diagnostic tests.
- Ongoing: Need for additional funding to support operations and growth.
- Potential: Technological obsolescence and the emergence of new diagnostic technologies.
- Ongoing: The company's current financial performance, including negative profit and gross margins, poses a significant risk to its long-term viability.
Growth Opportunities
- Expansion of Product Line: Cardio Diagnostics has the opportunity to develop and commercialize additional epigenetics-based diagnostic tests for other cardiovascular conditions. This could include tests for heart failure, stroke risk, and other related diseases. The market for cardiovascular diagnostics is estimated to reach $25 billion by 2028, providing a significant opportunity for growth. Timeline: 2-3 years.
- Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician practices to integrate Epi+Gen CHD into their diagnostic protocols can drive adoption and increase revenue. Strategic partnerships can provide access to a wider patient base and enhance the company's credibility. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, both domestically and internationally, can significantly increase the company's market reach. This could involve targeting regions with high prevalence of cardiovascular disease and unmet diagnostic needs. Timeline: 3-5 years.
- Development of Companion Diagnostics: Developing companion diagnostics that can be used to identify patients who are most likely to benefit from specific cardiovascular therapies can create a valuable niche market. This requires collaboration with pharmaceutical companies and a deep understanding of drug development. Timeline: 4-6 years.
- Direct-to-Consumer Testing: Offering Epi+Gen CHD directly to consumers through online platforms and partnerships with telehealth providers can expand access to the test and increase awareness. This requires careful consideration of regulatory requirements and ethical considerations. Timeline: 2-3 years.
Opportunities
- Expansion of product line
- Partnerships with healthcare providers
- Geographic expansion
- Development of companion diagnostics
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Need for additional funding
- Technological obsolescence
Competitive Advantages
- Proprietary epigenetics-based technology
- Focus on personalized medicine
- Early mover advantage in the epigenetics-based cardiovascular diagnostics market
About CDIO
Cardio Diagnostics Holdings, Inc., founded in 2017 and based in Chicago, Illinois, is a biotechnology company focused on developing and commercializing innovative, epigenetics-based clinical tests for cardiovascular disease. The company's primary offering is Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. This test utilizes a patient's epigenetic and genetic markers to provide a personalized risk assessment, aiding physicians in making more informed decisions about patient care. Cardio Diagnostics aims to improve the accuracy and efficiency of cardiovascular disease diagnosis and management through its proprietary technology. By focusing on epigenetics, the company seeks to identify risk factors that may not be apparent through traditional diagnostic methods. The company is relatively small, with 13 employees, reflecting its stage as an emerging player in the biotechnology sector. The company's focus on epigenetics places it within a growing area of personalized medicine, with the potential to expand its product offerings and market reach as it further develops its technology and establishes partnerships with healthcare providers.
What They Do
- Develops epigenetics-based clinical tests for cardiovascular disease.
- Commercializes diagnostic tests for risk assessment.
- Offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.
- Utilizes epigenetic and genetic markers for personalized risk assessment.
- Aids physicians in making informed decisions about patient care.
- Focuses on improving the accuracy and efficiency of cardiovascular disease diagnosis.
Business Model
- Develops and commercializes epigenetics-based clinical tests.
- Generates revenue through the sale of Epi+Gen CHD tests to healthcare providers and potentially direct-to-consumers.
- Focuses on personalized medicine and early disease detection.
Industry Context
Cardio Diagnostics Holdings, Inc. operates within the biotechnology industry, specifically focusing on cardiovascular disease diagnostics. The market for cardiovascular diagnostics is driven by the increasing prevalence of heart disease and the growing demand for early and accurate detection methods. The company's epigenetics-based approach positions it within the personalized medicine segment, which is experiencing rapid growth. Competitors include companies like ADIL, ADXN, BCDA, BCLI, and CELZ, which offer various diagnostic solutions. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements.
Key Customers
- Hospitals and clinics
- Physician practices
- Potentially direct-to-consumers through online platforms and telehealth providers
Financials
Chart & Info
Cardio Diagnostics Holdings, Inc. (CDIO) stock price: Price data unavailable
Latest News
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Mar 19, 2026
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Mar 13, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Mar 9, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Mar 3, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CDIO.
Price Targets
Wall Street price target analysis for CDIO.
MoonshotScore
What does this score mean?
The MoonshotScore rates CDIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Leadership: Meeshanthini V. Dogan
CEO
Meeshanthini V. Dogan serves as the CEO of Cardio Diagnostics Holdings, Inc. Her leadership is pivotal in guiding the company's strategic direction and overseeing its operations. With a background in healthcare and business management, she brings a wealth of experience to the role. Her expertise includes product development, market strategy, and financial management. She is responsible for managing the company's 13 employees and driving its growth initiatives. Her vision is to establish Cardio Diagnostics as a leader in epigenetics-based cardiovascular diagnostics.
Track Record: Under Meeshanthini V. Dogan's leadership, Cardio Diagnostics Holdings, Inc. has focused on developing and commercializing its Epi+Gen CHD test. She has overseen the company's efforts to establish partnerships with healthcare providers and expand its market reach. Her strategic decisions have been instrumental in positioning the company within the personalized medicine segment. Key milestones include the launch of Epi+Gen CHD and the development of the company's proprietary epigenetics-based technology.
What Investors Ask About Cardio Diagnostics Holdings, Inc. (CDIO)
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings, Inc. is a biotechnology company that develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its primary product is Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. The company utilizes a patient's epigenetic and genetic markers to provide a personalized risk assessment, aiding physicians in making more informed decisions about patient care. Cardio Diagnostics aims to improve the accuracy and efficiency of cardiovascular disease diagnosis and management through its proprietary technology, focusing on epigenetics to identify risk factors that may not be apparent through traditional diagnostic methods.
What do analysts say about CDIO stock?
As of 2026-03-15, there is no available AI analyst consensus on Cardio Diagnostics Holdings, Inc. (CDIO). Given the company's micro-cap status and focus on epigenetics-based diagnostics, valuation metrics may be highly speculative. Investors may want to evaluate the company's growth potential in the context of its financial challenges, including negative profit and gross margins. Further research is needed to assess the long-term viability and potential returns of CDIO stock. The company's success hinges on the successful commercialization and adoption of its Epi+Gen CHD test.
What are the main risks for CDIO?
The main risks for Cardio Diagnostics Holdings, Inc. include intense competition from established diagnostic companies, regulatory hurdles associated with FDA approval for new tests, and the need for additional funding to support operations and growth. The company's current financial performance, characterized by negative profit and gross margins, poses a significant risk to its long-term viability. Additionally, the rapid pace of technological advancements in the biotechnology industry could lead to technological obsolescence. Investors should carefully consider these risks before investing in CDIO.
What are the key factors to evaluate for CDIO?
Cardio Diagnostics Holdings, Inc. (CDIO) currently holds an AI score of 42/100, indicating low score. Key strength: Innovative epigenetics-based technology. Primary risk to monitor: Potential: Competition from established diagnostic companies with greater financial and marketing resources.. This is not financial advice.
How frequently does CDIO data refresh on this page?
CDIO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CDIO's recent stock price performance?
Recent price movement in Cardio Diagnostics Holdings, Inc. (CDIO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative epigenetics-based technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CDIO overvalued or undervalued right now?
Determining whether Cardio Diagnostics Holdings, Inc. (CDIO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CDIO?
Before investing in Cardio Diagnostics Holdings, Inc. (CDIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights in the future.
- The biotechnology industry is subject to rapid change and regulatory uncertainty.